The Food and Drug Administration (FDA) this week upgraded a recall of tens of thousands of bottles of a type of commonly prescribed thyroid medication.
Roughly 160,630 bottles of levothyroxine sodium tablets are under recall, the FDA said in multiple notices issued this week. The federal agency classified the levothyroxine sodium recall as Class II, which means that there is a moderate risk to public health.
The reason for the recalls is that the drug is deemed “subpotent” and the content of the medication is “below the approved specification,” the agency said.
The prescription-only drug is manufactured by India-based Intas Pharmaceuticals Limited for North Carolina-based Accord Healthcare, the FDA said. The levothyroxine sodium tablets come in different potencies and in different bottle sizes….